NCT03944434 - FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

December 27, 2024

Study Completion Date

November 27, 2025

Conditions

Breast Cancer

Interventions

DRUG

Ribociclib

ribociclib 600 mg/day orally

DRUG

Aromatase Inhibitors, non steroideal

letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally

DRUG

LHRH agonist

Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.

Trial Locations (1)

Hospital of Prato, Prato